GlassScriptPhysician profile
Sarit Kipnis
NPI 1164919759
$2,240.43
in general payments reported to CMS, 2019-2025
21 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $29.59 · 2024: $590 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.24 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $308.54 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.44 | 2024-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $144.17 | 2024-2025 | Tremfya |
| Genzyme Corporation | $137.11 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $129.64 | 2024-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $122.80 | 2025 | Tremfya |
| Qol Medical, LLC | $108.46 | 2024-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $90.55 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $77.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $63.02 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $59.69 | 2024-2025 | Ibsrela |
| Pfizer INC. | $52.41 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $49.06 | 2024-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $45.34 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $36.58 | 2025 | Monoferric |
| Daiichi Sankyo INC. | $28.65 | 2025 | Injectafer |
| Cumberland Pharmaceuticals, INC. | $26.90 | 2025 | Kristalose |
| Stryker Corporation | $25.82 | 2025 | Neptune |
| Gilead Sciences, INC. | $25.54 | 2025 | |
| Capsovision, INC. | $18.15 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarit Kipnis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.